CQA 206-291 in Parkinson's disease

R. F. Pfeiffer, R. Hofman

Research output: Contribution to journalArticlepeer-review


CQA 206-291, a mixed D1-D2 receptor agonist that also possesses dualistic dopamine antagonist-agonist properties, was investigated in a double-blind, placebo-controlled trial in individuals with Parkinson's disease of moderate severity. Significant improvement was noted in the treatment groups compared to the placebo group. Adverse effects were generally mild and transient. CQA appears to be an effective, well-tolerated agent in the treatment of Parkinson's disease. Nevertheless, because of laboratory-based toxicity concerns, CQA has been withdrawn from further human study and will not be developed clinically.

Original languageEnglish (US)
Pages (from-to)170-178
Number of pages9
JournalClinical neuropharmacology
Issue number2
StatePublished - 1991
Externally publishedYes


  • CQA 206-291
  • Dopamine agonists
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'CQA 206-291 in Parkinson's disease'. Together they form a unique fingerprint.

Cite this